Back to today’s briefing

Story perspectives

Intellia Raises $180 M, 62% Trial Success, Targets 2027 US Launch

6/5/2026

36 5 Full Breakdown

Summary

Story summary

Intellia Therapeutics announced a $180 million follow-on equity offering of 16.7 million shares at $10.75 each, raising proceeds from $150 million to $180 million at an 18.6% discount.
H.C. Wainwright cut its price target to $25 from $30 on May 13, citing dilution concerns.
In the Phase 3 lonvo-z trial, 62% of patients were attack-free and therapy-free with no adverse events.
Intellia plans a regulatory filing for a U.S. launch in early 2027.

History

Historical Context

The FDA’s August 2017 approval of Novartis’s CAR-T therapy Kymriah, the first U.S. gene-therapy step, and Spark Therapeutics’s December 2017 Luxturna launch demonstrated commercial viability for cellular medicines. Those milestones created investor expectations that now pressure companies such as Intellia Therapeutics to secure large capital for CRISPR programs, linking regulatory success to market financing.

1 of 2

Story summary

Intellia Therapeutics announced a $180 million follow-on equity offering of 16.7 million shares at $10.75 each, raising proceeds from $150 million to $180 million at an 18.6% discount.
H.C. Wainwright cut its price target to $25 from $30 on May 13, citing dilution concerns.
In the Phase 3 lonvo-z trial, 62% of patients were attack-free and therapy-free with no adverse events.
Intellia plans a regulatory filing for a U.S. launch in early 2027.

1 / 2